Home Sectors Healthcare Stock in the Spotlight: Regeneron Pharmaceuticals (NASDAQ: REGN)

Stock in the Spotlight: Regeneron Pharmaceuticals (NASDAQ: REGN)


Regeneron Pharmaceuticals trades as part of the healthcare sector and is in the biotechnology industry. The company CEO is Leonard S. Schleifer. Regeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Previous Intraday Trading Performance:

The REGN stock showed a previous change of 0.41% with an open at 409.37 and a close of 408.51. It reached an intraday high of 413.35 and a low of 403.00.

SeekingAlpha:  Regeneron: Cheap Enough To Look Past The Eylea Valley


The stock has a market cap of $44.6b with 109.3m shares outstanding, of which the float is 108.1m shares. Trading volume reached 545,236 shares compared to its average volume of 774,842 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Regeneron Pharmaceuticals shares returned -2.98% and in the past 30 trading days it returned 12.66%. Over three months, it changed 17.88%. In one year it has changed 19.21% and within that year its 52-week high was 431.32 and its 52-week low was 281.89. REGN stock is 44.92% above its 52 Week Low.

Our calculations show a 200 day moving average of 362.88 and a 50 day moving average of 390.59. Currently REGN stock is trading 12.58% above its 200 day moving average.

SeekingAlpha:  Sanofi and Regeneron to cut price of Praluent


The last annual fiscal EPS for the company was reported at 19.7 that ended on 31st of December 2018, which according to the previous close, that is a PE of 39.58. Based on 1 analyst estimate, the estimated EPS for the next quarter is 5.10. The TTM EPS is 19.70, which comes to a TTM PE of 20.74. Historically, the PE high was 197.40 and the PE low was 20.74. If the stock reached its PE low, that would represent a price of 408.51, which is a decrease of -0.00%.

The following are the last four quarter reported earnings per share:
12-31-2018:  5.92
09-30-2018:  5.10
06-30-2018:  4.70
03-31-2018:  3.98

Base on our calculations, the intrinsic value per share is 277.80, which means it may be overvalued by -47.05%

Indicators to Watch:

Based on the latest filings, there is 1.10% of insider ownership and 105.50% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.21

SeekingAlpha:  Regeneron reports positive data from Phase 3 EYLEA trial in diabetic retinopathy

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 32.81%, return on assets is 23.85%, profit margin is 38.84%, price-to-sales is 7.06 and price-to-book is 5.08.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 5  :Past Performance Score
 6  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.